Clinical trial
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00005652 |
|---|---|
| Title | Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopenic, Idiopathic |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 20 |
| Start date | Dec 1, 2000 |
| Primary completion | Aug 1, 2007 |
| First posted | May 3, 2000 |
| Last update posted | Sep 9, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: